These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Topical linezolid 0.2% for the treatment of vancomycin-resistant or vancomycin-intolerant gram-positive bacterial keratitis. Tu EY; Jain S Am J Ophthalmol; 2013 Jun; 155(6):1095-1098.e1. PubMed ID: 23453280 [TBL] [Abstract][Full Text] [Related]
46. [Treatment of vancomycin-resistant Enterococcus with linezolid in paediatric hospitals]. Travaglianti M; Pérez M; Sberna N; Rousseau M; Calle G; Gómez S Farm Hosp; 2007; 31(1):43-7. PubMed ID: 17439313 [TBL] [Abstract][Full Text] [Related]
47. Vancomycin-resistant enterococci infection and predisposing factors for infection and mortality in patients with acute leukaemia and febrile neutropenia. Kirkizlar TA; Akalin H; Kirkizlar O; Ozkalemkas F; Ozkocaman V; Kazak E; Ozakin C; Bulbul EN; Ozboz ES; Ali R Leuk Res; 2020 Dec; 99():106463. PubMed ID: 33130331 [TBL] [Abstract][Full Text] [Related]
48. Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: implications of daptomycin dose. Chuang YC; Lin HY; Chen PY; Lin CY; Wang JT; Chang SC Clin Microbiol Infect; 2016 Oct; 22(10):890.e1-890.e7. PubMed ID: 27475738 [TBL] [Abstract][Full Text] [Related]
49. Impact of different antimicrobial therapies on clinical and fiscal outcomes of patients with bacteremia due to vancomycin-resistant enterococci. Hayakawa K; Martin ET; Gudur UM; Marchaim D; Dalle D; Alshabani K; Muppavarapu KS; Jaydev F; Bathina P; Sundaragiri PR; Rajuri SD; Khatri J; Pogue JM; Lephart PR; Rybak MJ; Kaye KS Antimicrob Agents Chemother; 2014 Jul; 58(7):3968-75. PubMed ID: 24798267 [TBL] [Abstract][Full Text] [Related]
50. Linezolid in the treatment of vancomycin-resistant Enterococcus faecium in solid organ transplant recipients: report of a multicenter compassionate-use trial. El-Khoury J; Fishman JA Transpl Infect Dis; 2003 Sep; 5(3):121-5. PubMed ID: 14617299 [TBL] [Abstract][Full Text] [Related]
51. Treatment considerations in vancomycin-resistant enterococcal bacteremia: daptomycin or linezolid? A review. Shukla BS; Gauthier TP; Correa R; Smith L; Abbo L Int J Clin Pharm; 2013 Oct; 35(5):697-703. PubMed ID: 23893061 [TBL] [Abstract][Full Text] [Related]
52. Bacteremia caused by an Enterococcus faecalis isolate with high-level linezolid resistance in a teenager with Crohn's disease. Lopez Marti MG; Jhaveri R Pediatr Infect Dis J; 2009 Jul; 28(7):663-4. PubMed ID: 19451857 [TBL] [Abstract][Full Text] [Related]
53. Effects of daptomycin, linezolid, and vancomycin on establishment of intestinal colonization with vancomycin-resistant enterococci and extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae in mice. Pultz NJ; Stiefel U; Donskey CJ Antimicrob Agents Chemother; 2005 Aug; 49(8):3513-6. PubMed ID: 16048971 [TBL] [Abstract][Full Text] [Related]
54. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. McKinnon PS; Sorensen SV; Liu LZ; Itani KM Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705 [TBL] [Abstract][Full Text] [Related]
55. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. Steinkraus G; White R; Friedrich L J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693 [TBL] [Abstract][Full Text] [Related]
56. Outcomes of therapy: vancomycin-resistant enterococcal bacteremia in hematology and bone marrow transplant patients. Kraft S; Mackler E; Schlickman P; Welch K; DePestel DD Support Care Cancer; 2011 Dec; 19(12):1969-74. PubMed ID: 21110047 [TBL] [Abstract][Full Text] [Related]
57. Treatment of prosthetic valve infective endocarditis due to multi-resistant Gram-positive bacteria with linezolid. Wareham DW; Abbas H; Karcher AM; Das SS J Infect; 2006 Apr; 52(4):300-4. PubMed ID: 16099052 [TBL] [Abstract][Full Text] [Related]
58. [Update of antimicrobial resistance in Gram-positive microorganisms]. Cercenado E Med Clin (Barc); 2010 Dec; 135 Suppl 3():10-5. PubMed ID: 21477699 [TBL] [Abstract][Full Text] [Related]
59. Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents. Descourouez JL; Jorgenson MR; Wergin JE; Rose WE Antimicrob Agents Chemother; 2013 Mar; 57(3):1518-20. PubMed ID: 23263002 [TBL] [Abstract][Full Text] [Related]
60. Activity of linezolid and daptomycin against methicillin-resistant coagulase-negative staphylococci with increased MIC for vancomycin isolated from blood cultures in pediatric patients. Castagnola E; Amoroso L; Banov L; Faraci M; Loy A; Moscatelli A; Risso F; Barabino P; Ciucci A; Bandettini R J Chemother; 2014 Oct; 26(5):273-5. PubMed ID: 24070064 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]